Shares of vaccine makers moved higher early Monday following a CDC report that the U.S. was seeing a significant uptick in ...

Scientists discover that SARS-CoV-2 spike protein remains in the brain and skull bone marrow for years post-infection, ...

The University of Pennsylvania expects to receive $467 million from a German COVID-19 vaccine manufacturer after the pair ...

Five years ago, a cluster of people in Wuhan, China, fell sick with a virus never before seen in the world. The germ didn't ...

Five years after the start of Covid, we appear to be trying to teach ourselves the lessons of the pandemic the hard way.

Researchers have discovered that the SARS-CoV-2 spike protein persists in the brain and skull bone marrow for years after ...

I made four predictions about the stock market in 2024. The Fed indeed cut rates in Q4, but stocks didn't jump as much as I ...

University of Pennsylvania will receive $467 million from BioNTech as part of a settlement in a lawsuit over COVID-19 vaccine royalties, writes John George ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

A third dose of COVID-19 vaccine is beneficial among older Medicare beneficiaries, regardless of prior medically attended COVID-19 diagnoses.

Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.